Jeong Lee

Dynamic change of T315I BCR‐ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

Dong-Wook Kim, Soo-hyun Kim, Dongho Kim, 2009, Hematological oncology.

Analysis of Bcr‐Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P‐loop and T315I mutation is disease phase dependent

Dong-Wook Kim, Soo-hyun Kim, Se-Eun Jang, 2009, Hematological oncology.

Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy

Yoo-Jin Kim, Hyeoung-Joon Kim, Dong-Wook Kim, 2009, Leukemia & lymphoma.

Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.

B. Cho, Dong-Wook Kim, Soo-hyun Kim, 2009, Leukemia research.

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

Giuseppe Saglio, G. Saglio, Dong-Wook Kim, 2011, Leukemia & lymphoma.